Targeted Small Airways Therapy in Persistent Asthma

NCT ID: NCT01894048

Last Updated: 2019-09-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-28
• Study Completion Date: 2018-06-25

Brief Summary

The mainstay of asthma treatment is with inhaled steroids (commonly called a 'preventer') to keep the symptoms of asthma under control. Increasing strengths of steroid inhaler may be required in order to gain control of asthma, and this is usually guided both by symptoms and simple measurements of lung function such as peak flow.

The airways (breathing tubes) in the lungs get smaller the further into the lungs they go. Most simple measurements of lung function only reflect the larger 'central' airways and don't provide information on the smaller 'peripheral' airways.Newer measurements have been developed that can now give us accurate information on how the smaller airways are working.Indeed the small airways seem to play a significant role in asthma in terms of inflammation and airway narrowing.

Recently, new types of steroid inhalers have been developed that have a much smaller particle size than other standard inhaled steroids.These have been shown to go deeper into the lungs, thus getting into the smaller airways. There have been a few studies suggesting that this might improve asthma control. However, we do not know if when small airway function is shown to be abnormal, whether this improves with extra-fine particle inhaled steroids, nor whether by improving small airway function specifically this translates into improved asthma control.

In this study we wish to study asthmatic patients who are not completely controlled on standard particle size inhaled steroids, in addition to having evidence of abnormal small airway function. By doing this we want to find out whether changing to the same dose of an extra-fine particle inhaled steroid instead will improve asthma control by getting deeper into the lungs and improving small airway function.

Detailed Description

A single centre, open-label, single subject study over a 12-24 week period. Invited participants will receive a written 'Participant Information Sheet' (PIS) detailing the requirements of the trial and the extent of their participation before attending for a screening visit. Participants will be given at least 24 hours to read the PIS.

Prior to screen (and any subsequent challenge visit) participants will withhold LABAs (or combination inhaler containing LABA) for 48 hours; and salbutamol for 6 hours. Verbal consent will be obtained from the patient over the telephone for withholding medications prior to screen and it will be explained that this in no way means they have consented to the full study at this stage.

At the screening visit a member of the research team will discuss the PIS with the participant, answer any questions posed and written informed consent will be obtained and witnessed by the member of staff asking for the consent of the patient.

A general physical examination will be carried out by a qualified medical practitioner.

A pregnancy test will be performed on all female patients with advice issued to both male and female participants to use contraception throughout the duration of the study.

The following will be measured:

• Asthma Control Questionnaire
• Mini-Asthma Quality of Life Questionnaire
• Fractional exhaled nitric oxide levels
• Impulse oscillometry
• Spirometry
• Skin prick test to common allergens
• Full blood count, renal function, electrolytes, liver enzymes and random blood glucose.

Participants will be checked against all inclusion and exclusion criteria. Those found to be eligible will proceed to the step down and/or run-in period. This will last for a minimum of 4 weeks.

Participants will be issued with a pre-labelled container for the collection of an overnight urine sample the night prior to visit V1 with written instruction as to how this should be done. A sample will be collected prior to visits V2 and V3 as well.

If a potential participant who at screening is receiving ≥200µg/day ICS (BDP) without additional LABA has an ACQ >1.0 they will directly enter the 4 week run-in period.

At 2 weeks into the run-in period the participant will be contacted to reassess their ACQ score. If their ACQ>1.0 they will continue in the run-in period for the remaining 2 weeks at the same dose of ICS. If their ACQ is not >1.0 then their ICS dose will be approximately halved (or reduced to a minimum of 200µg/day if this is greater than half the original ICS dose) and one (if any) second line medication (e.g. theophylline, LTRA) will be discontinued at the discretion of a study doctor. They will then restart the 4 week run-in period. If they are already receiving 200µg/day ICS (i.e. the dose cannot be reduced further) then they will be withdrawn from the study at this juncture.

At the end of the 4 week period if the participant still has an ACQ>1.0 they will proceed to visit V1.

If a potential participant who at screening is receiving ≥200µg/day ICS (BDP) with additional LABA has an ACQ score >1.0, their LABA will be discontinued and they will directly enter the 4 week run-in period. If the participant is receiving their LABA as part of a combination inhaler, they will be converted to an equivalent ICS alone inhaler (i.e. coarse particle ICS) and enter the 4 week run-in period. Progress through run-in will then be as described before.

If a potential participant who at screening is receiving ≥200µg/day ICS (BDP) with additional LABA has an ACQ not >1.0, then their LABA will be discontinued as per 3.6.2 and their ICS dose will be approximately halved (or reduced to a minimum of 200µg/day if this is greater than half the original ICS dose). For example, Seretide 250µg b.i.d. would convert to Flixotide 125µg b.i.d. They will subsequently enter the 4 week run-in period progressing through it as described..

Participants will be asked to perform and record twice daily domiciliary PEF and to complete a daily diary of reliever use and symptoms from the beginning of the step-down/run-in period through to the end of the study. Participants will be advised to contact the investigators if they feel their asthma significantly worsening in the interim. They will also be given a card with 24 hour emergency contact details.

At the end of the 4 week run-in period, participants will be checked against all inclusion and exclusion criteria to confirm the subject's suitability to receive the study drug according to study protocol. Those eligible will proceed to study visit 1. Those who do not fulfil the study criteria will be returned to their pre-study medication and their GP informed of any medically relevant data.

Study visits V1, V2 and V3 Full study visits will occur at the end of the run-in period (baseline), at 4 weeks and 8 weeks.

Participants will be asked to withhold their reliever as per the screening visit. (LABAs are withheld for the duration of the study).

Participants will attend the unit on the morning of the visit day. The overnight urine collection will be received from the participant for analysis.

Peak flow records will be reviewed along with daily domiciliary symptom and reliever use diaries.

Participants will be asked to complete an ACQ and Mini-AQLQ. A venous blood sample will be drawn for FBC. A venous blood sample will be drawn for ECP. FeNO, IOS, and spirometry will be performed in that order. Mannitol bronchial challenge will then be performed

Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original ICS, e.g. Qvar 100µg = Clenil 200µg = Pulmicort 200µg = Flixotide 100µg = Asmanex 100µg. A Qvar 50µg or 100µg inhaler will be used to achieve this based on the dose requirement. An approximately equivalent inhaler device to the one the patient had been originally using will be used. Equally if the participant normally used a spacer device with their ICS, this will be provided to use with a Qvar pMDI.

A Participant Instruction and Appointment Leaflet will be issued, detailing:

Emergency contact numbers How to perform PEF How to write in the diary Record adverse events and concomitant medication use Withholding times for drugs The Patient Instruction Leaflet will be discussed fully with the subject and any questions answered

Participants will be issued with a pre-labelled container for the collection of an overnight urine sample the night prior to visits V2 and V3 respectively, with written instruction as to how this should be done.

Visit 2 (V2): Sections 3.7.2 to 3.7.10 and 3.7.13 will be repeated. Visit 3 (V3): Sections 3.7.2 to 3.7.10 will be repeated. The study will end at this point with the patient returned to their prescribed medications.

Conditions

Asthma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Qvar® (beclometasone dipropionate HFA)

Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.

Group Type: EXPERIMENTAL

Qvar® (beclometasone dipropionate HFA)

Intervention Type: DRUG

Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.

Interventions

Qvar® (beclometasone dipropionate HFA)

Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and female volunteers aged 18-65, with persistent asthma
• Asthma Control Questionnaire score >1.0 (at end of run-in)
• FEV1 >60% predicted
• R5>130% predicted and R5-R20>0.03kPa/L/s
• Ability to perform spirometry, impulse oscillometry, bronchial challenge and all domiciliary measurements
• Ability to give informed consent
• Asthmatic patients receiving treatment at Step 2, 3, or 4 of British Thoracic Society asthma guidelines
• Ability to withhold long-acting beta-agonists for the duration of the study

Exclusion Criteria

• Patients already receiving extra-fine particle inhaled corticosteroids (Qvar, Fostair, Alvesco)
• Pregnancy or lactation
• Known or suspected sensitivity to the Investigational Medicinal Product
• Inability to comply with protocol
• Any clinically significant medical conditions that may either endanger the health or safety of the participant, or jeopardise the protocol
• An asthma exacerbation requiring systemic steroid therapy or lower respiratory tract infection requiring antibiotics within 3 months prior to study commencement
• Participation in previous trial within 30 days

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: collaborator

University of Dundee

OTHER

Sponsor Role: lead

Responsible Party

Brian J Lipworth

Professor of Allergy and Immunology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Brian Lipworth, MD

Role: PRINCIPAL_INVESTIGATOR

University of Dundee

William Anderson, MBChB

Role: PRINCIPAL_INVESTIGATOR

University of Dundee

Locations

Brian Lipworth

Dundee, , United Kingdom

Countries

United Kingdom

References

Kuo CR, Jabbal S, Anderson W, Lipworth BJ. Pragmatic evaluation of inhaled corticosteroid particle size formulations on asthma control. Clin Exp Allergy. 2019 Oct;49(10):1321-1327. doi: 10.1111/cea.13453. Epub 2019 Aug 6.

Reference Type: RESULT

PMID: 31264282 (View on PubMed)

Other Identifiers

2012-003923-39

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

13/ES/0064

Identifier Type: OTHER

Identifier Source: secondary_id

2012RC16

Identifier Type: -

Identifier Source: org_study_id